SWISS-AMERICAN PARTNERS WITH TEMPUR-PEDIC MEDICAL TO DEVELOP RETAILER FOCUSED PROGRAM
Swiss-American Products Inc (Dallas,Tex) recently introduced the COMPLETE Program as part of its commitment to its relationship with Tempur-Pedic Medical. Swiss-American is an authorized distributor of Tempur-Pedic Medical products and developed the COMPLETE Program to support retailers who sell Tempur-Pedic Medical products.
COMPLETE is a support program available to qualifying direct medical suppliers. It consists of two components designed to drive customers to the retail stores and help grow institutional sales for Tempur- Pedic Medical dealers. COMPLETE offers special promotions and pricing to members of the program and members will have access to training in a variety of areas.
Visit http://www.elta.net for more information.
CARDIOVASCULAR BIOTHERAPEUTICS COMPLETES PHASE I WOUND HEALING TRIAL
CardioVascular BioTherapeutics Inc (Las Vegas, Nev) disclosed the completion of its Phase I wound healing clinical trial aimed at evaluating the safety and tolerability of the company’s protein-based drug candidate (CVBT-141B). This candidate is formulated with human fibroblasts growth factor-1 (FGF-1), in patients suffering from either diabetic or venous stasis ulcers.
FGF-1 was applied topically in 8 subjects at a single site and was well tolerated. According to the American College of Foot and Ankle Surgeons,15% of the estimated 20 million Americans afflicted with diabetes will develop a serious foot ulcer during their lifetime.A similar percentage of patients with chronic venous hypertension will also develop wounds.
FGF-1 offers the possibility of improved dermal ulcer healing by the promotion of new blood vessel growth (angiogenesis) in the wound bed resulting in enhanced development of granulation tissue and is able to fill wounds of almost any size.
Call 781-684-6532 for more information.
SUPREME MEDICAL PARTNERS WITH 3M HEALTHCARE TO PROMOTE CLINICAL EDUCATION
Supreme Medical Fulfillment Systems (Mobile,Ala) has collaborated with 3M Healthcare (St. Paul, Minn) to promote a clinical education program to its national customer base.This new marketing campaign features a series of clinical video presentations that are available to view free of charge on Supreme Medical’s corporate website.This will allow healthcare professionals to view application protocol demonstrations and clinical information regarding product usage, as well as provide wholesale pricing and reimbursement information to allow facilities to procure necessary wound care supplies.
The first clinical video featured on the website is Tegaderm AG™,3MHealthcare’s new ionic silver wound dressing. The video demonstration will be available for viewing through November 2007.
Visit http://www.suprememedical.com for more information.
THYMOSIN BETA-4 (Tβ-4) WOUND HEALING TECHNOLOGY RECEIVES US PATENT
RegeneRx Biopharmaceuticals Inc (Bethesda, Md) announced that a US patent designed for wound healing was issued through the US Patent and Trademark Office.The patent claims are based on a significant body of data developed by the National Institutes of Health and include numerous claims relating to thymosin beta 4 (Tβ-4), its analogues, related compounds, fragments, and other variants.
Tβ-4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class drug candidate that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. Tβ-4’s wound healing properties are the subject of 4 RegeneRx-sponsored Phase 2 clinical trials in chronic pressure ulcers, venous stasis ulcers, and epidermolysis bullosa.
Visit http://www.regenerx.com for more information.
